ESMO 2020 | Avelumab maintenance for urothelial cancer

Thomas Powles, MBBS, MCRP, Barts Cancer Institute, London, UK, discusses the use of avelumab maintenance in urothelial cancer (UC) as presented at ESMO 2020. Prof. Powles summarizes the use of avelumab first-line (1L) maintenance for patients with advanced UC, highlighting data from the Phase III JAVELIN Bladder 100 trial (NCT02603432). This study showed that avelumab 1L maintenance and best supportive care (BSC) prolonged the overall survival (OS) vs BSC alone in UC patients free from disease progression following 1L induction chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).